Patent: 10,597,381
✉ Email this page to a colleague
Summary for Patent: 10,597,381
Title: | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders |
Abstract: | The present invention provides, inter alia, a compound having the structure: ##STR00001## Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease. |
Inventor(s): | Stockwell; Brent R. (New York, NY), Dixon; Scott J. (New York, NY), Skouta; Rachid (New York, NY) |
Assignee: | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY) |
Application Number: | 16/247,354 |
Patent Claims: | see list of patent claims |
Details for Patent 10,597,381
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2032-04-02 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2032-04-02 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2032-04-02 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |